Navigation Links
Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery

hat the rate of death was significantly lower with Cleviprex than with sodium nitroprusside (1.7% vs. 4.7%, p = 0.045). Other than this difference, the primary endpoints -- rates of death, stroke, heart attack and kidney dysfunction -- were similar for Cleviprex compared to the other three agents.

About Perioperative Hypertension

Perioperative hypertension affects patients in the operating room, post- anesthesia care unit and intensive care unit. It is thought to be caused by the rapid shifts in blood volume and increased activity of the sympathetic nervous system that accompany surgery, which in turn increase vasoconstriction, vascular resistance, and both systolic and diastolic BP. The increased pressure can damage blood vessels, resulting in inflammation and leaking of fluid or blood into tissues, and complications such as hemorrhagic stroke, ischemic stroke, encephalopathy, myocardial ischemia or infarction, heart arrhythmia, congestive heart failure, and bleeding at the surgical site.

Perioperative hypertension is treated using intravenous antihypertensive agents, but current therapies have various shortcomings. For example, nitroglycerin and sodium nitroprusside dilate both arteries and veins, which can result in less predictable BP control. Nicardipine is selective for arteries, but because it has a slower onset and longer duration of action, and accumulates over time in the body, it is rarely used to control BP during surgery, and is only used occasionally after surgery.

About Cleviprex

Cleviprex is a novel, investigational drug rationally designed to meet the needs of the acute care practitioner for an intravenous hypertensive agent. It is the first third-generation dihydropyridine calcium channel blocker that acts rapidly and reliably, is vascular- and arterial-selective, and has an ultrashort half-life. Cleviprex recently completed Phase III clinical trials.

MDCO-G

About The Medicines Company

The Med
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Post Your Comments:
(Date:7/23/2014)... 2014  RT Oncology Services Corporation today announced that ... board of directors. Mr. Mundie is currently senior advisor ... on strategic projects within the company and on technology ... and strategy officer. Mike Martin ... "Craig is a visionary technology executive. His appointment is ...
(Date:7/23/2014)... BOHEMIA, N.Y. , July 23, 2014 /PRNewswire-iReach/ -- Top ... of GPM Pediatrics offers his feedback on article, which discusses ... Photo - http://photos.prnewswire.com/prnh/20140722/129440 According to ... of accidental injury and death among American children aged 1 ... inches of water." One expert in the article ...
(Date:7/23/2014)... , July 23, 2014  Mezzion Pharma Co. Ltd., ... evaluate the use of udenafil to treat adolescents who ... heart defects. The clinical program will follow protocols developed ... Pediatric Heart Network (PHN), a multi-center clinical research network ... (NHLBI) of the National Institutes of Health (NIH). ...
Breaking Medicine Technology:Craig Mundie Joins RainTree Oncology Board of Directors 2Craig Mundie Joins RainTree Oncology Board of Directors 3Premier Staten Island Pediatrician Dr. Michael Gabriel Comments On Article Discussing Pool Safety Tips for Parents 2Mezzion Pharma Initiates Clinical Development Program To Evaluate Udenafil In Adolescents With Single Ventricle Heart Defects 2
... Medical, Inc. (OTCBB: AEMD) announced today that its wholly ... ability of its Enzyme Linked Lectin Specific Assay (ELLSA) ... immunodeficiency virus (HIV), tuberculosis (TB), and various forms of ... July 2010, ESI disclosed that it filed a patent ...
... WARSAW, Ind., April 12, 2011 Zimmer Holdings, Inc. (NYSE: ... quarter 2011 sales and earnings conference call will be broadcast ... 8:00 a.m. Eastern Time.  A news release detailing the quarterly ... the morning of the conference call. The ...
Cached Medicine Technology:Aethlon Medical Announces Multi-Target Exosome Assay Validation 2Aethlon Medical Announces Multi-Target Exosome Assay Validation 3Aethlon Medical Announces Multi-Target Exosome Assay Validation 4Aethlon Medical Announces Multi-Target Exosome Assay Validation 5Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2011 Results 2
(Date:7/24/2014)... The Arm Lift, also known as brachioplasty, ... skin from the upper arms to create a more toned, ... arm can become lax and may begin to sag, resulting ... the appearance of sagging upper arms, and seek treatment to ... is now offering brachioplasty to tighten and improve the ...
(Date:7/24/2014)... The Republic of Tea, leading purveyor of premium teas, is ... celebrate “The Hundred-Foot Journey,” a new major motion picture produced ... journey begins in the moment when you bravely drop what ... is far out of your comfort zone. It is a ... the course of your life for the better. , ...
(Date:7/24/2014)... Jose, California (PRWEB) July 24, 2014 ... for sugar alcohols, commonly known as food polyols, is ... confectionery sectors. Rising incidence of obesity, growing awareness ... aging population vulnerable to diabetes are some of the ... With growing number of scientific studies validating the health ...
(Date:7/24/2014)... 24, 2014 Freeslate, Inc ... solutions for biopharmaceutical development, today announced its feature ... Formulations” by Jim Kling. Topics of this ... formulations and how automation can help address many ... formulations have been a growing focus of pharmaceutical ...
(Date:7/24/2014)... Imbue Partners is pleased to announce ... the National Women Business Owners Corporation ( NWBOC ). ... , Located near Boston, MA, Imbue Partners is ... growth through strategic planning, organizational competencies, and enabling processes. ... through teams, tools, and technologies for all phases of ...
Breaking Medicine News(10 mins):Health News:How to Get Toned Arms With Arm Lift Procedure 2Health News:How to Get Toned Arms With Arm Lift Procedure 3Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 2Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 3Health News:Rising Incidence of Diabetes and Obesity Drives the Global Sugar Alcohols Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of Diabetes and Obesity Drives the Global Sugar Alcohols Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Freeslate Featured in BioProcess International Article Discussing Challenges and Solutions to Highly Concentrated Protein Formulations 2Health News:Freeslate Featured in BioProcess International Article Discussing Challenges and Solutions to Highly Concentrated Protein Formulations 3Health News:Imbue Partners Certified as Woman-Owned Small Business 2
... the first long-term randomized trial of a chemopreventive agent for ... cancer in the drug-treated group may be attributable to shrinkage ... The study of the Prostate Cancer Prevention Trial, led by ... Gann, is published in the Sept. 12 issue of the ...
... Providers, SEATTLE, Sept. 12 , News Facts -- ... concerns and interests to the 2008 presidential candidates ... online physician community. -- The initiative is enabling U.S. licensed ... via individual web-based videos. Experts from a ...
... Wrinkles, HIGHLANDS, N.J., Sept. 12 Fifty really ... men in their 40s and 50s look better than,their ... can look incredibly sexy at any age. So ... keep the,attention of handsome himbos and beautiful babes? Biocap, ...
... Corporation,(Nasdaq: KNSY ) today announced that it will ... 30, 2007 at 7:00 A.M. Eastern Time on,Friday, October ... be hosting a teleconference,discussing the earnings results on Friday, ... participate in the teleconference call, dial 1-651-291-5254. The,teleconference call ...
... billion dollars. , But an unhealthy kidney costs moreabout ... associate professor in the division of nephrology and hypertension ... about $17 billion a year to care for patients ... currently over 320,000 people undergoing hemodialysis in the United ...
... Centers Head and Neck Cancer Center is teaming up ... cancer. The clinical alliance between Mount Sinai and ENT ... allergy and audiology practice in the tri-state area, together ... quality care, cancer screening and advanced surgical options for ...
Cached Medicine News:Health News:Shrinkage of prostate led to overestimation of cancer risk in trial 2Health News:U.S. Physicians Question Presidential Candidates 2Health News:Cougars Crave Biocap, The Haute Pepper Wrinkle Eraser 2Health News:Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference 2Health News:Clinical trials present better alternatives for dialysis patients 2Health News:Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: